Actively Recruiting
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Led by Immunocore Ltd · Updated on 2026-01-28
600
Participants Needed
13
Research Sites
202 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
CONDITIONS
Official Title
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- HLA-A*02:01-positive
- Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma
- Archived or fresh tumor tissue sample confirmed as adequate
- Evaluable/measurable disease per RECIST 1.1
- Previously received applicable standard treatments
- Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective birth control methods
You will not qualify if you...
- Symptomatic or untreated central nervous system metastasis
- Recent bowel obstruction
- Ongoing ascites or effusion requiring recent drainages
- Significant ongoing toxicity from prior anticancer treatment
- Out-of-range laboratory values
- Clinically significant lung, heart, or autoimmune disease
- Ongoing requirement for immunosuppressive treatment
- Significant secondary malignancy
- Hypersensitivity to study drug or excipients
- Pregnant or lactating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
St Vincent's Hospital
Darlinghurst, Sydney, Australia, NSW 2010
Active, Not Recruiting
2
Peter MacCallum Cancer Centre
Melbourne, Australia
Actively Recruiting
3
Institut Jules Bordet
Anderlecht, Belgium, 1070
Actively Recruiting
4
Universitair Ziekenhuis Gent
Ghent, Belgium
Actively Recruiting
5
UZ Leuven
Leuven, Belgium, 3000
Actively Recruiting
6
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Actively Recruiting
7
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Actively Recruiting
8
nstituto Clinico Humanitas
Rozzano, Italy, 20089
Actively Recruiting
9
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Actively Recruiting
10
Hospital HM Nou Delfos
Barcelona, Spain
Actively Recruiting
11
VHIO, Vall d'Hebron University Hospital
Barcelona, Spain
Actively Recruiting
12
Centro Integral Oncologico Clara Campal
Madrid, Spain
Actively Recruiting
13
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Actively Recruiting
Research Team
I
Immunocore Medical Information
CONTACT
I
Immunocore Medical Information EU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here